Citations

Showing 10 of 107961 citations.

Development of North American Consensus Guidelines for Medical Laboratories That Perform and Interpret Platelet Function Testing Using Light Transmission Aggregometry
Hayward, Catherine P.M. , Moffat, Karen A. , Raby, Anne, Israels, Sara J. , Plumhoff, Elizabeth, Flynn, Greg, Zehnder, James L.

Mayo Clinic

American Journal of Clinical Pathology | November 18, 2010 | Volume: 134 | Issue: 6 | Pages: 955-963

10.1309/ajcp9v3rrvnzmkds | PMID 21088160 Get It

Abstract Platelet function testing is important for the diagnostic evaluation of common and rare bleeding disorders. Our study goals were to promote best practices and reduce unnecessary testing variances by developing North American guidelines on platelet function testing. Guidelines were developed by consensus for expert recommendations (minimum level for approval, 70%) that included recommendations on the evaluation and interpretation of light transmission platelet aggregometry (LTA). To assess consensus, medical opinions on recommendations were gathered from diagnostic laboratories that perform LTA, in collaboration with the Quality Management Program–Laboratory Services (QMP-LS) in Ontario, Canada (10 laboratories), and the North American Specialized Coagulation Laboratory Association (NASCOLA; 47 laboratories, 5 overlapping the QMP-LS group). Adequate consensus was achieved for all and 89% of recommendations for the QMP-LS and NASCOLA groups, respectively. The recommendations adopted provide North American laboratories with additional guidance on platelet function testing, including how to interpret LTA abnormalities.
Intracellular signaling pathways regulating net protein balance following diaphragm muscle denervation
Argadine, Heather M., Mantilla, Carlos B. , Zhan, Wen-Zhi, Sieck, Gary C. , Gransee, Heather M. , Sieck, Gary , Gransee, Heather M , Mantilla, Carlos B

Mayo Clinic

American Journal of Physiology-Cell Physiology | November 18, 2010 | Volume: 300 | Issue: 2 | Pages: C318-C327

10.1152/ajpcell.00172.2010 | PMID 21084642 Get It

Unilateral denervation (DNV) of rat diaphragm muscle increases protein synthesis at 3 days after DNV (DNV-3D) and degradation at DNV-5D, such that net protein breakdown is evident by DNV-5D. On the basis of existing models of protein balance, we examined DNV-induced changes in Akt, AMP-activated protein kinase (AMPK), and ERK½ activation, which can lead to increased protein synthesis via mammalian target of rapamycin (mTOR)/p70S6 kinase (p70S6K), glycogen synthase kinase-3β (GSK3β), or eukaryotic initiation factor 4E (eIF4E), and increased protein degradation via forkhead box protein O (FoxO). Protein phosphorylation was measured using Western analyses through DNV-5D. Akt phosphorylation decreased at 1 h and 6 h after DNV compared with sham despite decreased AMPK phosphorylation. Both Akt and AMPK phosphorylation returned to sham levels by DNV-1D. Phosphorylation of their downstream effector mTOR (Ser2481) did not change at any time point after DNV, and phosphorylated p70S6K and eIF4E-binding protein 1 (4EBP1) increased only by DNV-5D. In contrast, ERK½ phosphorylation and its downstream effector eIF4E increased 1.7-fold at DNV-1D and phosphorylated GSK3β increased 1.5-fold at DNV-3D ( P < 0.05 for both comparisons). Thus, following DNV there are differential effects on protein synthetic pathways with preferential activation of GSK3β and eIF4E over p70S6K. FoxO1 nuclear translocation occurred by DNV-1D, consistent with its role in increasing expression of atrogenes necessary for subsequent ubiquitin-proteasome activation evident by DNV-5D. On the basis of our results, increased protein synthesis following DNV is associated with changes in ERK½-dependent pathways, but protein degradation results from downregulation of Akt and nuclear translocation of FoxO1. No single trigger is responsible for protein balance following DNV. Protein balance in skeletal muscle depends on multiple synthetic/degradation pathways that should be studied in concert.
Early Events in Retrovirus XMRV Infection of the Wild-Derived MouseMus pahari
Sakuma, Toshie, Tonne, Jason M., Squillace, Karen A., Ohmine, Seiga, Thatava, Tayaramma, Peng, Kah-Whye , Barry, Michael A. , Ikeda, Yasuhiro , Barry, Michael A

Mayo Clinic

Journal of Virology | November 18, 2010 | Volume: 85 | Issue: 3 | Pages: 1205-1213

10.1128/jvi.00886-10 | PMID 21084477 Get It

ABSTRACTA novel gammaretrovirus, xenotropic murine leukemia virus-related virus (XMRV), has been identified in patients with prostate cancer and in patients with chronic fatigue syndromes. StandardMus musculuslaboratory mice lack a functional XPR1 receptor for XMRV and are therefore not a suitable model for the virus. In contrast, Gairdner's shrew-mice (Mus pahari) do express functional XPR1. To determine whetherMus paharicould serve as a model for XMRV, primaryMus paharifibroblasts and mice were infected with cell-free XMRV. Infection of cellsin vitroresulted in XMRV Gag expression and the production of XMRV virions. After intraperitoneal injection of XMRV intoMus paharimice, XMRV proviral DNA could be detected in spleen, blood, and brain. Intravenous administration of a green fluorescent protein (GFP) vector pseudotyped with XMRV produced GFP+CD4+T cells and CD19+B cells. Mice mounted adaptive immune responses against XMRV, as evidenced by the production of neutralizing and Env- and Gag-specific antibodies. Prominent G-to-A hypermutations were also found in viral genomes isolated from the spleen, suggesting intracellular restriction of XMRV infection by APOBEC3in vivo. These data demonstrate infection ofMus pahariby XMRV, potential cell tropism of the virus, and immunological and intracellular restriction of virus infectionin vivo. These data support the use ofMus paharias a model for XMRV pathogenesis and as a platform for vaccine and drug development against this potential human pathogen.
Analytical construct of reversible desensitization of pituitary-testicular signaling: illustrative application in aging
Keenan, Daniel M., Iranmanesh, Ali , Veldhuis, Johannes D.

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | November 17, 2010 | Volume: 300 | Issue: 2 | Pages: R349-R360

10.1152/ajpregu.00477.2010 | PMID 21084679 Get It

Luteinizing hormone (LH) administered in pharmacological amounts downregulates Leydig cell steroidogenesis. Whether reversible downregulation of physiological gonadotropin drive operates in vivo is unknown. Most of the analytical models of dose-response functions that have been constructed are biased by the assumption that no downregulation exists. The present study employs a new analytical platform to quantify potential (but not required) pulsatile cycles of LH-testosterone (T) dose-response stimulation, desensitization, and recovery (pulse-by-pulse hysteresis) in 26 healthy men sampled every 10 min for 24 h. A sensitivity-downregulation hysteresis construct predicted marked hysteresis with a median time delay to LH dose-response inflection within individual T pulses of 23 min and with median T pulse onset and recovery LH sensitivities of 1.1 and 0.10 slope unit, respectively ( P < 0.001). A potency-downregulation model yielded median estimates of one-half maximally stimulatory LH concentrations (EC50 values) of 0.66 and 7.5 IU/l for onset and recovery, respectively ( P < 0.001). An efficacy-downregulation formulation of hysteresis forecasts median LH efficacies of 20 and 8.3 ng·dl−1·min−1 for onset and offset of T secretory burst, respectively ( P = 0.002). Segmentation of the LH-T data by age suggested greater sensitivity, higher EC50 (increased LH potency), and markedly (2.7-fold) attenuated LH efficacy in older individuals. Each of the three hysteresis models yielded a marked ( P < 0.005) reduction in estimated model residual error compared with no hysteresis. In summary, model-based analyses allowing for (but not requiring) reversible pituitary-gonadal effector-response downregulation are consistent with a hypothesis of recurrent, brief cycles of LH-dependent stimulation, desensitization, and recovery of pulsatile T secretion in vivo and an age-associated reduction of LH efficacy. Prospective studies would be required to prove this aging effect.
Myocardial Infarction Outcomes
Roger, Véronique L.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | November 16, 2010 | Volume: 3 | Issue: 6 | Pages: 568-570

10.1161/circoutcomes.110.959163 | PMID 21081746 Get It

Neural control of the bladder
Benarroch, Eduardo E.

Mayo Clinic

Neurology | November 15, 2010 | Volume: 75 | Issue: 20 | Pages: 1839-1846

10.1212/wnl.0b013e3181fdabba | PMID 21079186 Get It

Hb Cambridge-MA [β144(HC1)-β146(HC3)Lys-Tyr-His→0 (HBB c.433 A>T)]: A New High Oxygen Affinity Variant
Oliveira, Jennifer L. , Swanson, Kenneth C., Wendt, Patricia, Caughey, Thomas, Hoyer, James D., Herrick, Jennifer L.

Mayo Clinic

Hemoglobin | November 15, 2010 | Volume: 34 | Issue: 6 | Pages: 565-571

10.3109/03630269.2010.526921 | PMID 21077764 Get It

Shock Wave Lithotripsy is Not Predictive of Hypertension Among Community Stone Formers at Long-Term Followup
Krambeck, Amy E. , Li, Xujian, Bergstralh, Eric J., Gettman, Matthew T., Rule, Andrew D. , Lieske, John C.

Mayo Clinic

Journal of Urology | November 14, 2010 | Volume: 185 | Issue: 1 | Pages: 164-169

10.1016/j.juro.2010.09.033 | PMID 21074794 Get It

Corin Is Present in the Normal Human Heart, Kidney, and Blood, with Pro–B-Type Natriuretic Peptide Processing in the Circulation
Ichiki, Tomoko , Huntley, Brenda K., Heublein, Denise M., Sandberg, Sharon M., Martín, Fernando L., Jougasaki, Michihisa , Burnett, John C. , McKie, Paul M.

Mayo Clinic

Clinical Chemistry | November 13, 2010 | Volume: 57 | Issue: 1 | Pages: 40-47

10.1373/clinchem.2010.153908 | PMID 21075870 Get It

BACKGROUNDB-type natriuretic peptide (BNP), which is activated in heart failure (HF), is processed to an active form by corin. The corin gene is expressed in the human heart and kidney, but corin protein expression in the heart, kidney, and circulation, along with whether proBNP is processed by circulating corin, remains unknown.METHODSWe examined corin protein expression by immunostaining and Western blot in human heart and kidney, and we assessed the circulating corin concentration by ELISA. We examined histidine-tagged (His-tag) proBNP1–108 processing in serum and plasma by immunoprecipitation and Western blot and sequenced the processed form.RESULTSNormal human heart and kidney displayed the presence of corin, especially in cells around the vasculature. Both corin and proBNP1–108 were present in the plasma of healthy human subjects, with circulating corin significantly higher in men than women (P &lt; 0.0001) and a positive correlation of corin to age (P = 0.0497, r = 0.27). In fresh normal plasma and serum, His-tag proBNP1–108 was processed to a lower molecular weight form confirmed to be BNP. Processed BNP was higher in men than women (P = 0.041) and was positively correlated to plasma corin concentrations (P = 0.041, r = 0.65).CONCLUSIONSOur results support the concept that proBNP1–108 may be processed outside of the heart in the circulation where the proprotein convertase is present. Moreover, sex may impact this process, since corin concentrations are higher in men. These findings may have important physiologic and pathophysiologic implications for the proBNP/corin system in the human.
The Effect of Dutasteride on the Usefulness of Prostate Specific Antigen for the Diagnosis of High Grade and Clinically Relevant Prostate Cancer in Men With a Previous Negative Biopsy: Results From the REDUCE Study
Andriole, Gerald L. , Bostwick, David G., Brawley, Otis W. , Gomella, Leonard G. , Marberger, Michael, Montorsi, Francesco , Pettaway, Curtis A. , Tammela, Teuvo L.J. , Telöken, Cláudio , Tindall, Donald J., Freedland, Stephen J. , Somerville, Matthew C. , Wilson, Timothy H., Fowler, Ivy L., Castro, Ramiro, Rittmaster, Roger S., Group, REDUCE Study, Larcher, Alessandro , Group, REDUCE Study

Mayo Clinic

Journal of Urology | November 13, 2010 | Volume: 185 | Issue: 1 | Pages: 126-131

10.1016/j.juro.2010.09.011 | PMID 21074214 Get It